Vanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs. The company’s portfolio includes products in the areas of psychiatry, neurology, and dermatology, among others. Vanda is committed to improving patient outcomes through research and development of novel treatments. Key projects include treatments for conditions such as schizophrenia, non-24-hour sleep-wake disorder, and atopic dermatitis. Vanda’s objectives consist of advancing its clinical development programs, expanding its product portfolio through strategic partnerships and acquisitions, and delivering sustainable growth. The company strives to make a meaningful difference in patients' lives through its pioneering work in the healthcare sector.